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Comparison of Intravenous Lorcainide With Lidocaine for Acute 
Therapy of Complex Ventricular Arrhythmias: 
Results of a Randomized Study With Crossover Option 
JEFFREY L. ANDERSON, MD, FACC, MARIA ANASTASIOU-NANA, MD, JOAN R. LUTZ, RN, 
STEVEN L. WRITER, MD 
Salt Lake City, Utah 
There is a need for effective, well tolerated, intraveno"s 
antiarrhythmic agents. The effects of lorcainide, a new 
class I antiarrhythmic agent, were compared with those 
of lidocaine in a randomized parallel study with cross-
over option in 30 hospitalized patients with frequent (> 
IImin) complex ven.ricular arrhythmias. Lorcainide 
loading dose was ~ mg/kg (at 2 mg/min) supplemented, 
if needed, with lOOmg in I hour; maintenallce dose was 
8 mg/h, Lidocaine loading dose was 1 mg/kg (at 25 mg/min) 
supplemented, if needed, with 50 mg in 2 minutes; main-
tenance dose was 2 or 3 mg/min (as needed). Arrhytb-
Mias were compared for 2 hours before and after drug 
loading. Initially responding patients (rninillium of 70% 
arrhythmia suppression) were continued on mainte-
nance therapy for 24 hours. Patients initially failing or 
with later arrhythmia escape crOliSed Over to alternating 
therapy (seven to lidocaine, nine to lorcainide). 
The median frequency of premature ventricular com-
plexes decreased by 76% after lidocaine (p < 0.05) and 
by 93% after 10fcainide (p < 0.001); this difference ap-
proached significallce (p = 0.06). More than 95% ar-
rhythmia suppr~sion was achieved by lorcainide in 47 % 
of patients and by lidocaine in only 13% (p < 0.05). 
Couplets d~reased by a median of 100% after lorcainide 
and by 89% after lidocaine. Couplets were eliminated 
A review of current antiarrhythmic drugs suggests the need 
for developing versatile new agents, particularly those ef-
fective by both intravenous and oral routes 0,2). Currently, 
lidocaine is the agent of choice for intravenous therapy of 
most ventricular arrhythmias, but it is neither universally 
well tolerated nor universally effective (3,4). Furthermore, 
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in 62 % of the patients after lorcainide and in 27 % after 
lidocaine (p = 0.06), There was 100% suppression of 
runs of premature beats in 11 patients after lorcainide 
and 99% suppression in 10 patients after lidocaine. In 
patients crossing over, lorcainide led to greater suppres-
sion of premature ventricular complexes in six of nine 
patients (67%) compared with none qf seven patients 
(0%) (p < 0.01) crossing over to lidocaine. Adverse ef-
fects were minor after both drugs; effects on vital signs 
and the electrocardiogram were insignificant. After 
loading, plasma lidocaine level averaged 2.5 ± 1.5 ",g/rol 
and was maintained at 2.1 to 4.1 ~g/ml. Lorcainide 
concentration averaged 0.47 ± 0.23 ",g/ml after loading, 
but decreased to between 0.18 and 0.25 ",glml during 
maintenance. Arrhythmia escape was noted later in sb: 
patients whose complex ventricular arrhythmias were 
initially controlled with lorcainide and was associated 
with decreasing levels in blood. 
In summary, lorcainide proved to be a well tolerated, 
efficacious antiarrhythmic agent when administered in-
travenously for acute therapy of complex ventricular 
arrhythmias and appeared to be geQerally superior to 
lidocaine. However, bigher maintenance doses are 
suggested. 
() Am Coil CardioI1985;5:333-41) 
in responding patients requiring oral therapy, another drug 
must be used. 
Lorcainide hydrochloride is a new acetanilide derivative 
with demonstrated antiarrhythmic properties which can be 
effectively administered either intravenously or orally (5). 
Its pharmacologic and antiarrhythmic properties have been 
demonstrated in both animal models (6-9) and patients 
(l 0-15). Studies in patients have examined the antiar-
rhythmic effects of lorcainide after either single intravenous 
doses or at least I week of oral therapy. 
Lorcainide has local anesthetic properties and markedly 
slows intraventricular conduction (depression of phase 0 of 
the action potential) while affecting repolarization only 
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modestly, which is characteristic of a class I-C antiar-
rhythmic drug (16). The disposition of oral lorcainide is 
complicated, involving saturable first pass hepatic metab-
olism and the gradual appearance of an active metabolite, 
norlorcainide (11,15,\7,18). These considerations do not 
apply to acute intravenous therapy, however. After intra-
venous lorcainide, the distribution and elimination half-lives 
are approximately I and 8 hours, respectively (10,15,17,18). 
Intravenous lorcainide is well tolerated hemodynamically 
(6-8,14,15). 
Although single dose intravenous lorc?inide studies have 
been performed, comparisons of efficacy and tolerance against 
standard therapy (that is, lidocaine) have not been made, 
nor have effects of prolonged infusion regimens been care-
fully studied. For this reason, we undertook a prospective 
randomized comparison of intravenous lorcainide with lid-
ocaine for the acute rpanagement of complex ventricular 
arrhythmias in hospitalized patients. 
Methods 
Patient selection criteria and entry characteristics. 
Criteria for inclusion of patients included the presence of 
significant. complex ventricular arrhythmias. potentially life-
threatening or requiring therapy. Criteria for complex ar-
rhythmias included frequency of premature ventricular com-
plexes of 60/h or more, couplets of 5/h or more. early beats 
(R on T phenomenon) or ventricular tachycardia (three or 
more premature ventricular complexes in succession). Ad-
mission to the coronary care unit and informed consent were 
required for entry into the study. Exclusion criteria included 
pregnancy, cardiogenic shock or uncontrolled congestive 
heart failure, second or third degree atrioventricular (A V) 
junctional block, complete left bundle branch or bifascicular 
block, uncontrolled arterial hypertension (> 170/100 mm 
Hg) and clinically advanced hepatic or renal disease or other 
terminal illness. Patients with acute myocardial infarction 
were not studied. Concurrent antiarrhythmic medications 
were not allowed. and all previous medication was discon-
tinued for at least four half-lives. Beta-adrenergic blocking 
agents and digitalis were permitted only if required for ther-
apy of other cardiovascular disease (that is, angina and 
congestive heart failure, respectively). 
Thirty patients were entered into the study (Table 1 J. 
There were 23 men and 7 women with an average age of 
63 years (range 22 to 84). Underlying heart disease included 
ischemic disease in 18 (16 with previous myocardial in-
farction), valvular heart disease in 3. dilated cardio-
myopathy in 5 and primary electrical disease (with no ev-
ident structural disease) in 4. Eleven patients gave a history 
of congestive heart failure; 12 had undergone coronary by-
pass surgery. Left ventricular ejection fraction. available in 
12 before therapy, averaged 0.41 ± 0.15. The patients were 
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Table 1. Patient Characterization by Initial Drug Assignment 
Group:j: 
Characteristic 
Number 
Sex (% male) 
Age (yr)* 
Previous antiarrhythmic drugs (n)* 
Coronary artery diseaset 
Valvular/myocardial disease 
Idiopathic disease 
Lorcainide 
15 
80 
60 ± 15 
3.5 ± 1.4 
53% 
33% 
13% 
Lidocaine 
15 
73 
65 ± 14 
3.2 ± 2.0 
66% 
20% 
13% 
*Values are mean ± standard deviation. tTwo patients also had as-
sociated valvular disease. :j:No differepces between groups were significant. 
characterized by an average of 3.3 ± I. 7 unsuccessful 
antiarrhythmic drug triqls (due to intolerance or inefficacy) 
and frequent complex arrhythmias on Holter monitor re-
cordings. Patient characteristics by initial drug assignment 
were similar. 
Study design. The study was designed as a randomized 
parallel acute intervention protocol with the primary objec-
tive being the response during the first 4. hours after loading. 
Response was also noted for intravenous maintenance ther-
apy over 24 hours, with a crossover option in patients in 
whom the drug failed. Although this was a short-term study 
and included potentially life-threatening arrhythmias. base-
line 24 hour electrocardiographic recordings before anti-
arrhythmic therapy were obtained whenever possible. In two 
patients with ongoing ventricular tachycardia. therapy was 
initiated after the 2 hour predrug control period. In the other 
28 patients, an average of 20.0 ± 4.7 monitored control 
hours (range 7.5 to 24) was obtained. After obtaining in-
formed consent and a monitored documentation of the qual-
ifying arrhythmia, a randomized treatment plan with either 
lorcainide or lidocaine was initi~ted. Ventricular arrhythmia 
was documented directly by tryndscription (Trendscriber, 
American Optical) during a 2 h9ur lead-in control period, 
during initial drug loading and for 2 hours after the last 
loading infusion. Quantitative Holter monitor recording 
(Marquette system) was used for additional documentation 
of antiarrhythmic response initially and fpr subsequent re-
sponse over 24 hours. 
Lorcainide dosing regimen. Lorcainide was given as a 
2.0 mg/kg intravenous infusion at a rate of 2 mg/min. After 
completion of the loading dose, a maintenance infusion was 
initiated at a rate of 200 mg/24 h (8 mg/h). In the event 
that satisfactory arrhythmia control (>85% suppression) 
was not achieved after completion of the initial infusion. an 
additional 100 mg over I hour was infused. The rate of 
maintenance infusion after a second loading dose was also 
200 mg/24 h except for patients weighing more than 75 kg, 
in whom 300 mg124 h was allowed (three primary and two 
secondary trials). Patients failing to achieve adequate ar-
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rhythmia control (minimum of 70% arrhythmia suppres-
sion/2 h after loading) were crossed over to lidocaine therapy 
as follows. 
Lidocaine dosing regiihen. LIdocaine was administered 
at an initial dose of 1,0 mg/kg at art infusion rate of 25 
mg/min. After completion of the loading dose, a mainte-
nance infusion was initiated at 2.0 mg/min and then con-
tinued for up to 24 hours, In the event that satisfactory 
arrhythmia control was not achieved (criteria just outlined), 
an additional bolus of 50 mg was administered and the 
subsequent infusion rate increased to 3.0 mg/min. If sat-
isfactory arrhythmia control was still not achieved, the lor-
cainioe treatment regimen was instituted. A minimal delay 
of three drug elimination half-lives was allowed before 
crossbver except in patients with severely symptomatic or 
life-threatening arrhythmia (ventricUlar tachycardia). In pa-
tients crossing over more than 4 hours after Initial therapy, 
a new 2 hour control period was obtained after previous 
drug washout and before alternative drug therapy. 
Clinical observations. Continuous electrocardiographic 
observation together with 24 hour Holter monitoring and 
initial trerltlscription (first 6 hours as defined) were obtained. 
Vital signs were measured frequently and recorded before 
study, at the end of acute therapy (2 hours) and at 6, 12, 
IS and 24 hours. Complete blood count, 20 channel blood 
biochemistry survl::y and (where possible) urinalysis were 
obtained befo~ study ahd within 24 hours of study completion. 
Blood samples for drug levels. Blood samples for de-
termination of lorcainide and lidocaihe plasma concentra-
tions were drawn before study, 5 minutes after the com-
pletion of each loading dose and at hours I, 2, 4, 8, 12, 
IS and 24. Samples were drawn from the arm opposite the 
infusion site. Lidocaine levels were determined locally (LOS 
Hospital laboratory) using a standard clinical assay (fluo-
rescence polarization immunoassay method). The therapeu-
tic lidocaine range has been determined to be 1.2 to 5.0 
/-Lg/ml. For lorcainide assay, blood was centrifuged im-
mediately and plasma separated and frozen. Samples were 
analyzed by Janssen Pharmaceutica nv Veerse, Belgium. 
Plasma concentrations of lorcainide were determined ac-
cordihg to the method of Woestenborghs, which is based 
on a specific high pressure gas-liquid chromatographic 
procedure, 
Statistical methods. Because arrhythmia freqJency re-
sponses were not normally distributed, nonparametric meth-
ods were used to establish statistical significance (19). The 
Wilcoxon rank-sum method was used for paired sample 
analysis of ventricular arrhythmia frequency during the 2 
hour control period versus the 2 hour period after loading. 
(A significance level of p < 0.005 was considered definitive 
of a group antiarrhythmic response.) The Mann-Whitney 
test was used for two-sample (unpaired) testing of antiar-
rhythmic reSponse (percent suppression) to lorcainide versus 
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lidocaine. Arrhythmia frequency is reported as both median 
and mean response together with range, also because of 
non normal distributions. Chi-square analysis was performed 
for evaluation of data in 2 x 2 contingency tables, A prob-
ability (p) level of less than 0,05 (two-tailed) was considered 
significant. 
Results 
Baseline arrhythmia frequency. The frequency of pre-
mature ventricular complexes on the baseline Holter re-
cording (mean 20 hours) averaged 792/h (range 87 to 2,570) 
in 2S patients. The frequency was similar in the 13 patients 
randomized to initial lorcainide therapy (832/h, range 210 
to 2,570) and the 15 randomized to initial lidocaine therapy 
(757/h, range 87 to 2,221). Similar ectopic beat frequencies 
were also observed in these patients during the 2 hour lead-
in control period: 773/h (range 53 to 2,023, n = 15) overall, 
with 936/h (range 182 to 1,873) for the lorcainide group 
and 632/h (range 53 to 2,032) for the lidocaine group (p = 
NS, lidocaine versus lorcainide). These data suggest stable 
temporal arrhythmia frequencies in our patients, In addition, 
two patients with sustained ventricular tachycardia (rates of 
130 and 152 beats/min, respectively) were randomized to 
lorcainide: adding these two patients yields a mean 2 h 
predrug ectopic beat frequency of 1,600/h for all patients 
in the lorcainide group. 
Arrhythmia response to lorcainide. Arrhythmia sup-
pression was highly significant after drug loading for the 
15 patients initially assigned to lorcainide (p < < 0,00 I, 
Wilcoxon) (Fig. I). The median premature ventricular com-
plex frequency decreased 93%, from 884/h before to 65/h 
after lorcainide. Mean premature ventricular complex 
suppression was 87%, from a mean of 1,600/h (range 182 
to 7,800 l sustained ventricular tachycardiaj) to 203/h (range 
o to (79). 
Individual percent suppression (~l premature ventricular 
complexes is presented in FiKure 2, The median response 
was 90% suppression, and the mean percent suppression 
was 79%. Only I patient showed a lack of suppression 
( - I 1%), I I showed more than 70% suppression and 7 had 
more than 99% suppression. Five responded fully to the 
initial loading infusion, and 10 received the supplemental 
loading dose. 
Two patients presented with sustained, nonhypotensive 
ventricular tachycardia. In both, conversion to normal sinus 
rhythm occurred before the end of the initial lorcainide 
loading dose, In the other 13 patients, the median hourly 
frequency of couplets decreased 100% from 29/h before to 
O/h after lorcainide. The mean couplet decrease was 99%, 
from 40 to 0.5/h. In nine patients initially with nonsustained 
runs of ventricular ectopic complexes, the mean number of 
runs decreased 100%, from 7 to O/h. 
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Figure 1. Individual patient responses for 15 primary lorcainide 
(LOR) trials (left) and 15 primary lidocaine (LID) trials (right). 
Values for the average frequency per hour of premature ventricular 
complexes, logarithmic scale for 2 hours before drug (control, C) 
and for 2 hours after final drug loading are plotted. Open circles 
(-0-) represent logarithmic mean values. 
Arrhythmia response to lidocaine. The overall re-
sponse of premature ventricular complex frequency to lid-
ocaine for the 15 Initial trials was of marginal statistical 
significance (p < 0.05, Wilcoxon). Individual responses 
are presented in Figure I. The median frequency of pre-
mature ventricular complexes decreased 76%, from 344/h 
before to 8-2/h after lidocaine. The mean rate of ectopic beat 
suppression was 35%, from 632/h (range 146 to 2,023) to 
410/h (range 9 to 1,467). 
Individual percent suppression of premature ventricular 
complexes for patients initially given lidocaine is presented 
in Figure 3. The median percent respohse was 84% suppres-
sion, and the mean percent suppression was 54%. Increased 
frequency of premature complexes occurred in three patients 
(suppression -54, -16 and -13%, respectively); there 
was more than 70% suppression in eight. 
The frequency of ventricular couplets declined 89%, from 
a median of 9/h before to I/h after therapy. The mean percent 
couplet suppression was also 89%, from 23/h before to 2.6/h 
after therapy. In 10 patients initially with ventricular runs, 
the mean run number decreased 99%, from 12/h before tei 
O. 15/h after lidocaine. 
Comparative primary responses to lorcainide versus 
lidocaine. The average percent arrhythmia suppression in 
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FigUre 2. Individual percent premature ventricular complex (PVC) 
suppression (ordinate) for 15 primary lorcainide trials. Premature 
ventricular complex suppression determined for :2 hours after drug 
loading versus 2 hours before administration of the drug. Patient 
(pt.) entry number (no.) is shown in parentheses on the abscissa 
next to the response bar. 
response to lorcainide versus lidocaine (Fig. 2 versus Fig. 
3) bordered on statistical significance (p = 0.06, Mann-
Whitney). Responders achieved a higher degree of ectopic 
beat suppression with lorcainide (Fig. 4). At the level of 
50% suppression of ventricular ectopic beats, lorcainide was 
successful in 87% of patients, compared with 60% for lid-
ocaine. At the level of 80% suppression, the corresponding 
percents were 67% (lorcainide) and 53% (iidocaine). Of 
note, seven (47%) lorcainide-treated patients achieved more 
Figure 3. Individual percent premature ventricular complex (pVC) 
suppression for 15 primary lidocaine trials. Format as in Figure 
2. 
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Figure 4. Percent of patients achieving various levels of total 
premature ventricular complex (PYC) suppression for primary ( 1°) 
trials of the two drugs. Significant comparisons arc given in the 
figure. 
than 95% ectopic beat suppression (all> 99%) compared 
with one (13%) lidocaine-treated patient (none > 99%) 
(p < 0.05). 
The level oj'suppression oj' ventricular couplets also dU~ 
fered hy treatment (Fig. 5); 100% of patients receiving 
lorcainide achieved at least 75% suppression of couplets 
compared with 73% of those receiving lidocaine (p < 0.(5). 
At the level of 90% suppression, lorcainide was successful 
in 92% and lidocaine in 67% of patients. Couplets were 
eliminated in 62% of those receiving lorcainide compared 
with 26% of those receiving lidocaine. The suppression of 
ventricular runs or tachycardia was also slightly greater with 
lorcainide (see earlier), but occurrences were too infrequent 
for comparison. 
Figure 5. Percent of patients achieving various levels of suppres-
sion of ventricular couplets. Format similar to Figure 4. 
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Response in patients crossing over to alternate ther-
apy. The comparative response of premature ventricular 
complex frequency to both therapies in the 16 patients cross-
ing over to alternate therapy is shown in Figure 6. Response 
(relative to control) refers to the initial 2 hour observation 
period. (Two patients initially treated successfully with lid-
ocaine and four treated successfully with lorcainide crossed 
over later because of arrhythmia recurrence during main-
tenance therapy.) Crossover to lorcainide therapy after lid-
ocaine resulted in significantly increased frequency of ven-
tricular ectopic beats in one, but decreased frequency and 
improved suppression in six of nine trials. In contrast, cross-
over from lorcainide to lidocaine therapy resulted in in-
creased arrhythmia frequency in each of seven trials. The 
chance of improved suppression during crossover favored 
the lidocaine to lorcainide sequence at p < 0.01. 
Including hoth primary and crossover trials, lorcainide 
resulted in a mean arrhythmia suppression rate (n = 24 
trials) of 78%, from 1,351 to 300/h; the median frequency 
decreased by 92%. Overall, the mean suppression rate for 
lidocaine was 37% (n = 22 trials), from 865 to 546/h; 
median frequency after lidocaine decreased 83%. The over-
all mean rate of suppression of couplets for lorcainide and 
lidocaine (all trials) was 95 and 87%, respectively, and for 
runs, 100 and 99%, respectively. 
Response of vital signs and electrocardiogram. Mean 
values for vital signs and electrocardiographic intervals are 
presented in Table 2 for the control period, together with 
Figure 6, Comparative responses for the 15 crossover trials. Paired 
observations are given on the left for patients crossing over from 
primary lidocaine (I ° LID) to secondary lorcainide (2° LOR) ther-
apy and on the right for patients crossing over from primary 
lorcainide (I ° LOR) to secondary lidocaine (2° LID) therapy. Pre-
mature ventricular complex (PYC) frequency for 2 hours after 
loading is presented as a percent of predrug control on the ordinate. 
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Table 2. Vital Signs and Electrocardiographic Intervals 
a Variable* 
Post -Lorcainide Post-Lidocaine 
Variable Control (2 h) (2 h) 
Heart rate (beats/min) 83 ± 4 +2 +4 
PR interval (ms) 186 ± 9 +7 -3 
QRS complex (ms) 91 ± 3 +1 -2 
QT interval (ms) 362 ± 7 +2 -9 
SBP (mm Hg) 117 ± 3 -2 +1 
DBP (mm Hg) 68 ± 2 +5 +6 
*No changes achieved significance. Values are mean ± standard error. DBP = diastolic blood pressure; 
SBP = systolic blood pressure. 
average changes occurring at the end of the 2 hour primary 
treatment observation period. Small differences by therapy 
that did not achieve statistical significance were noted. These 
included negligible changes in heart rate and diastolic pres-
sure and minor decreases in systolic blood pressure for both 
drugs. Lorcainide tended to increase electrocardiographic 
intervals and lidocaine to decrease them slightly, but the 
trends were not significant. No adverse individual hemo-
dynamic or electrocardiographic changes occurred. 
Plasma drug concentrations. Therapeutic plasma con-
centrations of lidocaine were achieved during loading and 
maintained during continued infusion therapy. Lidocaine 
concentrations 5 minutes after the final bolus (two boluses 
in 18 of 22 trials) averaged 2.4 J.Lg/ml. These were well 
maintained at I and 2 hours, with averages of 2.1 J.Lg/ml. 
Concentrations at 0 to 2 hours did not differ in patients in 
whom therapy succeeded or failed. With continued main-
tenance therapy, 3 mg/min in 18 of 22 trials, lidocaine 
concentrations tended to gradually increase, as reported by 
others (20), to an average value of 4.1 J.Lg/ml in the nine 
patients continued on therapy to 18 to 24 hours. 
Initial lorcainide therapy resulted in mean plasma con-
centrations of 0.47 ± 0.23 J.Lg/ml at the end of loading 
(supplemental infusion given in 15 of 24 trials). A sub-
stantial decrease in levels occurred by 1 hour to 0.29J.Lg/ml, 
and at 2 hours to 0.25 J.Lg/ml. Responding patients did not 
have higher lorcainide plasma concentrations at 0 to 2 hours 
than those observed in patients in whom treatment failed. 
A further decline occurred during continued maintenance 
therapy to a nadir of O. 18 ± O. 12 J.Lg/ml at 12 to 18 hours 
(n = 14). 
Observations during 24 hour maintenance therapy. 
Maintenance therapy for longer than 2 hours (initial re-
sponders) was continued in 19 (79%) of 24 total lorcainide 
trials and 13 (59%) of 22 total lidocaine trials. Thirteen 
lorcainide trials and nine lidocaine trials were continued 
through the entire 24 hours. Six late discontinuations of 
lorcainide therapy occurred at 3, 3, 4, 4, 6 and II hours, 
respectively. Four late discontinuations of lidocaine therapy 
occurred at 4, 6, 12 and 12 hours, respectively. 
Median suppression in arrhythmia frequency in patients 
who continued in primary lidocaine and primary lorcainide 
trials is presented together with plasma drug level trends in 
Figure 7. Parallel but contrasting trends in plasma drug 
concentrations and median responses are noted for both 
drugs in the patients who continued therapy. A modest par-
allel decline in lorcainide response, associated with decreas-
ing levels in blood, is also noted (Fig. 7 A). An average 
increase in lidocaine efficacy among responding patients 
was associated with increasing average drug levels (Fig. 
7B). 
Adverse reactions (Table 3). Severe adverse reactions 
requiring discontinuation of either drug did not occur. Mod-
erate neurologic effects requiring lidocaine dosage reduction 
were observed in two trials during maintenance therapy. In 
contrast, minor neurocirculatory complaints were common, 
occurring in 9 of 15 initial trials with lorcainide and in an 
identical proportion with lidocaine. Crossover trials were 
associated with a similar incidence of adverse reactions. 
These minor reactions typically included dizziness, pares-
thesias or drowsiness during lidocaine and a sensation of 
warmth, flushing, diaphoresis or dizziness during lorcain-
ide. One patient developed accelerated junctional rhythm 
during lorcainide, but had a history of similar episodes be-
fore therapy. The frequency of isolated ventricular ectopic 
beats increased above the baseline value in 7 of 46 drug 
trials, but no clinically important proarrhythmic effects oc-
curred (that is, no substantial increases in couplets or runs). 
No biochemical or hematologic changes were ascribed to 
either drug. 
Discussion 
The results of our study suggest lorcainide to be a highly 
effective antiarrhythmic agent for the initial control of com-
plex arrhythmias in hospitalized patients. Lorcainide was 
superior to lidocaine, both as primary therapy and crossover 
therapy. Of particular note were two patients with sustained 
nonhypotensive ventricular tachycardia whose arrhythmia 
converted and who were maintained in normal sinus rhythm 
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Figure 7. Comparisons of efficacy and plasma drug 
concentrations (Cp) during the 24 hour observation 
period for primary trials in continuing patients. Lor-
cain ide values are shown in A and lidocaine values 
in 8, Median values for individual percent pre-
mature ventricular complex (PVC) suppression are 
given in upper curves as closed circles with hor-
izontal lines, indicating 2 hour periods of obser-
vation, Scales are given on the left ordinate. Num-
ber of patients studied at each interval is shown in 
parentheses on the abscissa, Corresponding average 
plasma drug concentrations are also shown in lower 
curves as closed circles with vertical bars, de-
noting the standard errOL Drug concentration scales 
are given on the right ordinate, 
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during lorcainide therapy, No clinically significant proar-
rhythmic effects (induction of ventricular tachycardia) oc-
curred even though an increase in ventricular ectopic beats 
was rarely noted, as observed for all antiarrhythmic agents 
(21), Furthermore, symptomatic tolerance to intravenous 
lorcainide was excellent and comparable with or better than 
tolerance to lidocaine, No patients required lorcainide dose 
reduction because of adverse effects, Electrocardiographic 
and hemodynamic effects were minor for both drug regimens, 
Table 3. Adverse Effects 
Severity/Type 
Severe, stop drug 
Moderate, t dose 
Mild (neurocirculatory reactions) 
Primary trial 
Secondary trial 
t = decrease, 
Lorcainide 
(n = 24) 
o 
o 
9115 
6/9 
Drug 
Lidocaine 
(n = 22) 
o 
2 
9/15 
317 
Limitations of standard intravenous antiarrhythmic 
therapy (lidocaine). Lidocaine has been the primary agent 
for acute therapy of ventricular arrhythmias, with the ad-
vantage of moderate antiarrhythmic efficacy and generally 
excellent hemodynamic tolerance (3), However, lidocaine 
is neither universally well tolerated nor universally effec-
tive, Lidocaine also demonstrated only modest overall ef-
ficacy in a previous study (4) from our institution (mean 
arrhythmia reduction of 40%) in which it was compared 
with another new class I antiarrhythmic agent, pirmenoL 
Mean lidocaine concentration averaged 4,4 JLg/ml in that 
study, resulting in neurologic adverse reactions in two-thirds 
of the patients, Similarly, oral lidocaine-congener therapy 
(tocainide, mexiletine) has generally proved less effective 
than oral therapy with standard and newer class I agents 
including class I-e drugs (22), 
Intravenous procainamide is currently the only com-
monly used alternative to lidocaine for intravenous antiar-
rhythmic therapy (I), Although procainamide also is effec-
tive orally, the high incidence of adverse reactions during 
long-term therapy, including a 30% incidence of drug-
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induced lupus erythematosus suggests that it is not an ideal 
agent in this regard. 
The efficacy and adverse effect profile for lidocaine in 
the present study is consistent with previously published 
experience (1,3,4): a moderate efficacy rate (mean ventric-
ular ectopic beat suppression of 35%, but median response 
of 76%) and a moderately high rate of adverse effects (60% 
with neurologic effects), most of which were tolerable (two 
required dosage reduction). Our lidocaine administration 
regimen was designed to mimic that used in common clinical 
practice, with most patients receiving two closely spaced 
loading bolus injections and an infusion rate of 3 mg/min. 
With this regimen, average lidocaine concentrations (2.1 to 
4.1 /Lg/ml) were determined to be in the mid therapeutic 
range (1.2 to 5.0 /Lg/ml) throughout the study period. Our 
study does not exclude the possibility that modest additional 
efficacy might be obtained by higher lidocaine dosages (that 
is, a third bolus injection and 2:4 mg/min infusion). How-
ever, clinical practice together with our own adverse ex-
perience profile suggest that this is not likely to be a gen-
erally tolerable dosage. Moreover, minimal lidocaine plasma 
levels (at I to 2 hours) were identical in nonresponders and 
responders. 
Excellent initial efficacy of intravenous lorcainide. 
Our experience with intravenous lorcainide confirms and 
also extends previous experience with respect to efficacy 
and tolerance (10-15). The initial loading regimen was well 
tolerated and resulted in a high rate of efficacy on the basis 
of both the percent of patients responding (II [73%1 of 15) 
and the degree of response (median suppression 93%, mean 
87; 7 with >99% suppression). This degree of suppression 
has been characteristic of and relatively unique to class 
I-C agents (23-25). The response to lorcainide becomes more 
impressive in view of the selected nature of the patients in 
this study, with most having undergone multiple prior 
antiarrhythmic trials (average 3.3). 
Breakthrough arrhythmias during maintenance lor-
cainide. The initial excellent response to intravenous lor-
cainide was diminished to some extent by later arrhythmia 
breakthrough. Late discontinuations of lorcainide therapy 
occurred in 6 (32%) of 19 initially successful trials. The 
median response also decreased somewhat with time in re-
sponding patients (Fig. 7). Possible explanations for this 
decline in responsiveness include: I) inadequate mainte-
nance of plasma concentration during continued therapy, 
and 2) changing pharmacologic effect over time (tolerance). 
The first explanation is supported by the findings in our 
study. Mean lorcainide concentrations decreased to 50% of 
the postIoading levels by 2 hours (to 0.25 /Lg/ml) and de-
clined further by 12 to 18 hours (to 0.18 /Lg/ml). This 
decrease was paralleled by a general decline in the median 
response in patients who continued therapy (Fig. 7 A). 
The suggested therapeutic range of 0.04 to 0.2 /Lg/ml 
for plasma lorcainide concentration during oral therapy (26) 
lACC Vol. 5, No.2 
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cannot readily be extrapolated to intravenous therapy be-
cause of the importance of the metabolite norlorcainide in 
achieving antiarrhythmic effects during long-term oral 
administration (15). Previous intravenous lorcainide studies 
generally have consisted of single dose infusions of I to 2 
mg/kg. Meinertz et al. (18) noted that lower plasma con-
centrations were required to produce the same QRS wid-
ening after oral than after intravenous administration. A 20% 
QRS widening was achieved at plasma concentrations of 
about 0.2 /Lg/ml after oral drug, but required concentrations 
of 0.5 /Lg/ml after intravenous drug. A relation was also 
shown between concentration of drug in plasma, its dynamic 
effects (QRS widening) and the antiarrhythmic effects (ec-
topic beat suppression). The minor degrees of electrocar-
diographic interval prolongation seen at 2 hours in our study 
(Table I) when plasma lorcainide averaged 0.25 /Lg/ml are 
in keeping with this plasma concentration-effect relation for 
intravenous drug (I 8). 
The development of tolerance appears to be an unlikely 
explanation for late arrhythmia breakthrough. Meinertz et al. 
(I 8) noted that higher concentrations of lorcainide were 
required to induce antiarrhythmic effects during initial drug 
infusion than during the postinfusion period. During the 
postinfusion period, decay in antiarrhythmic effect was much 
more gradual than decline in plasma drug concentration. 
Similarly, gradual metabolism of lorcainide to norIorcainide 
(not measured) during the maintenance infusion period in 
our study would be expected to augment rather than detract 
from antiarrhythmic effect (\5). 
Dosage recommendations for future studies. As an 
initial trial with longer-term (I day) intravenous lorcainide 
infusions, the present study was designed with a conser-
vative dosage regimen. However, because adverse reactions 
were minor (none requiring dosage reduction and most oc-
curring during the initial infusion), an increased mainte-
nance infusion rate is suggested in future studies. Our data 
are not adequate to establish a reliable concentration-
response relation. It appears reasonable, however, to at-
tempt to maintain the plasma concentrations attained at the 
end of our loading infusions (about 0.4 ± 0.2 /Lg/ml). 
Assuming approximately linear kinetics, a dosage increment 
during maintenance therapy of up to twofold would be 
suggested. 
Design limitations of present study. The limitations of 
our study should be kept in mind. We performed a short-
term intervention study in a select group of patients. Because 
of the nature of the patient group, long-term baseline re-
cordings could not be obtained. However, an average of 20 
hours of baseline recording (in 28 patients) was obtained. 
A verage arrhythmia frequency per hour was similar to that 
of the 2 hour drug baseline value, indicating stable arrhyth-
mia mechanisms. Because of the clinical nature of the study, 
crossover to opposite drug was performed only in patients 
showing an inadequate response at some time. For this rea-
l
1
1
1
Of f
lACC Vol. 5, No.2 
February 1985:333--41 
son, the parallel portion of the study (primary drug trials) 
was emphasized in the response evaluation. Similarly, clin-
ical considerations overruled a final placebo washout phase. 
However, the high rate of initial response, the differences 
in response between parallel therapies and the high rate of 
later breakthrough all argued strongly against spontaneous 
variations as explanations for effects during initial drug ther-
apy (27), The present study does not provide information 
concerning the value of response to intravenous lorcainide 
as a predictor of response to long-term oral therapy. How-
ever, it is of interest that in the 15 patients subsequently 
receiving long-term oral lorcainide therapy, response was 
equal to or greater than that to intravenous drug administration. 
Conclusion. A clinical protocol for initial and longer-
term administration of intravenous lorcainide was tested. 
Previous studies have focused on single dose intravenous 
lorcainide. Our study confirms the strategy used for initial 
loading, and excellent efficacy and tolerance were observed. 
After lorcainide loading, plasma concentrations during 
maintenance therapy decreased and were associated with 
breakthrough arrhythmias in some patients. This suggests 
that higher maintenance infusion rates should be considered 
in future trials. Lorcainide appears to be a promising new 
drug for intravenous use in the therapy of acute ventricular 
arrhythmias and a welcome addition to the limited resources 
currently available. 
We thank the housestaff, nursing personnel and attending physicians in· 
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